NovaDigm Therapeutics has reported the positive preclinical study results of its NDV-3 vaccine to treat vulvovaginal candidiasis (VVC).
NDV-3 is a prophylactic vaccine candidate which contains a recombinant Candida surface protein, Als3, and an adjuvant Alhydrogel.
The study is designed to assess the efficacy of the vaccine to treat both fungal caused by Candida albicans and bacterial pathogens by methicillin-resistant Staphylococcus aureus (MRSA).
The study showed that vaccination with NDV-3 induced potent, protective immune responses against VVC with high anti-NDV-3 antibodies thus led to decreases in vaginal fungal burden.
NovaDigm CEO Timothy Cooke said this preclinical efficacy data for NDV-3 in a specific fungal disease indication further supports prior preclinical data, and also complements the positive immune response activity that NovaDigm recently reported from the Phase 1 trial for this vaccine.